Vivatlac synbiotic for gut bacteria in IBS
Official title: Effects of Vivatlac Synbiotic on the Gut Microbiota of Patients With Irritable Bowel Syndrome - A Randomized, Double-blind, Placebo-Controlled, 12 Weeks Clinical Trial
Run by The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz · NCT07235228 · Data updated 2026-11-12
We will test whether taking one Vivatlac synbiotic capsule daily for 12 weeks changes gut bacteria and helps adults with moderate to severe IBS.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz Academic / other |
| Locations | 2 sites (Jarocin and 1 other locations) |
| Status | Recruiting |
| Started | November 21, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | December 17, 2025 |
| Trial ID | NCT07235228 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with IBS using the WGO IBS questionnaire who have moderate to severe symptoms (IBS-SSS ≥ 175) and who have not used probiotics or antibiotics in the past 3 months are ideal candidates.
✕Probably not a fit
People with mild IBS, recent antibiotic or probiotic use, other chronic bowel diseases, or major uncontrolled medical conditions are unlikely to benefit or be eligible for this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multi-center, randomized, double-blind, placebo-controlled trial with a four-week screening phase followed by 12 weeks of treatment. Eligible adults with moderate to severe IBS (IBS-SSS ≥ 175) will be randomized to one capsule per day of a nine-strain synbiotic (total 4.5 × 10^9 CFU plus 68 mg FOS) or matching placebo. Patients will record symptoms and stool characteristics in a diary and provide samples for gut microbiota analysis to compare changes between groups. The trial aims to link microbiota shifts with symptom changes under blinded, controlled conditions.
Why it matters
Potential benefit: If successful, the synbiotic could reduce IBS symptoms and help normalize gut microbiota in patients with moderate to severe IBS.
How similar studies have gone: Previous probiotic and synbiotic trials in IBS have shown mixed results with some modest symptom improvements, so this approach has supportive but not definitive evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosed for Irritable Bowel Syndrome using the IBS questionnaire for Health Care Providers of the World Global Gastroenterology Organization * IBS severity assessed with the IBS-Severity Scoring System (IBS-SSS) being ≥ 175 points (indicating medium or severe IBS). Exclusion Criteria: * patients currently taking products containing probiotics or have taken this kind of products during the last 3 months * patients currently taking antibiotics or have taken antibiotics during the last 3 months * patients having a concurrent severe illness (malignancies, uncontrolled hypertension or diabetes, hepatic, renal or cardiac dysfunctions, serious neurological disorders, psychosis, respiratory disorders such as asthma or COPD, hyper- or hypothyroidism * patients having chronic bowel disorders other than IBS, including inflammatory bowel disease, gastroenteritis, stomach and duodenal cancer, celiac disease * patient being tested positive for presence of Clostridioides difficile * patient being pregnant, lactating, or planning to become pregnant during the next 3 months * patient being diagnosed to have a lactose intolerance * patients using motility drugs or dietary fiber supplements withing 2 weeks before study start * patient taking anti-coagulant medication * patients have participated in another clinical trial within the last three months
Where it's running
-
State Hospital Jarocin
Jarocin, Poland Recruiting -
State Hospital Jarocin
Jarocin, Poland Recruiting
Study contacts
- Principal investigator: Jacek Piatek, Prof. Dr. — The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
- Study coordinator: Jacek Piatek, Prof. Dr.
- Email: drpiatek@interia.eu
- Phone: +48883389788
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
Repeated transcranial magnetic stimulation to treat diarrhea-predominant irritable bowel syndrome
This study will test whether repeated transcranial magnetic stimulation (rTMS) can reduce diarrhea, abdominal pain, and improve quality of life in adults with IBS-D.
-
Brenipatide (LY3537031) for IBS with constipation
This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.
-
Brenipatide (LY3537031) treatment for adults with IBS‑D
This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.
-
Camlipixant for IBS-D and IBS-M: a test in adults
This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.
-
Defining Objective Markers of Dietary Compliance in IBS
This study tests whether a biomarker in stool or urine can reflect how much certain carbohydrates you eat, helping manage IBS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.